Q4 2024 DiaMedica Therapeutics Inc Earnings Call Transcript
Key Points
- DiaMedica Therapeutics Inc (DMAC) has made significant progress in its preeclampsia clinical program, obtaining ethics approval and beginning dosing in South Africa.
- The company's DM199 treatment shows promise due to its safety profile, ability to produce nitric oxide, and potential to lower blood pressure without crossing the placental barrier.
- The stroke program has activated 30 clinical sites, increasing the potential for steady enrollment and expanding the eligible patient population.
- The ReMEDy2 trial protocol allows for refrigerated storage of DM199, simplifying logistics for patient treatment over a three-week period.
- DiaMedica Therapeutics Inc (DMAC) has a strong financial position with $44.1 million in cash and investments, providing a runway into Q3 of 2026.
- Enrollment in the ReMEDy2 trial has been slower than expected due to lower staffing levels in research units post-COVID.
- The company has updated its expectations for interim analysis to the first half of 2026, indicating delays in trial progress.
- Research and development expenses increased significantly to $19.1 million in 2024, driven by the continuation of the ReMEDy2 trial and expansion of the clinical team.
- The company anticipates only moderate increases in R&D expenses, which may limit the pace of clinical development.
- Despite progress, the company acknowledges that the enrollment rate is still not at the desired level, impacting trial timelines.
Thank you, operator. Hello everyone and welcome to our full year 2024.
Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics full year 2024 conference call. An audio recording of the webcast will be available.
Shortly after the call today on DiaMedica's website at www.diamedica.com in the investor relations section.
Before DiaMedica proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements.
More information, including factors that could cause actual results to differ from projected results, appears in the section entitled Cautionary Note regarding forward-looking statements in the company's press release issued yesterday and under the heading risk factors
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
